{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:00:25Z","timestamp":1792400425571,"version":"4.4.0"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.vaccine.2011.12.060","type":"journal-article","created":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T17:38:37Z","timestamp":1337189917000},"page":"B10-B17","source":"Crossref","is-referenced-by-count":56,"special_numbering":"S2","title":["History of meningococcal vaccines and their serological correlates of protection"],"prefix":"10.1016","volume":"30","author":[{"given":"Caroline","family":"Vipond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Care","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Feavers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.vaccine.2011.12.060_bib0005","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2011.12.060_bib0010","series-title":"Handbook of Meningococcal Disease","first-page":"17","article-title":"The population biology of Neisseria meningitidis: implications for meningococcal disease, epidemiology and control","author":"Maiden","year":"2006"},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.060_bib0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/clinids\/5.1.71","article-title":"Meningococcal disease: still with us","volume":"5","author":"Peltola","year":"1983","journal-title":"Rev Infect Dis"},{"issue":"3846","key":"10.1016\/j.vaccine.2011.12.060_bib0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"issue":"4140","key":"10.1016\/j.vaccine.2011.12.060_bib0025","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/bmj.1.4140.757","article-title":"Recent knowledge of the incidence and control of cerebrospinal fever","volume":"1","author":"Underwood","year":"1940","journal-title":"Br Med J"},{"key":"10.1016\/j.vaccine.2011.12.060_bib0030","doi-asserted-by":"crossref","unstructured":"Greenwood M. The outbreak of cerebrospinal fever at salisbury in 1914-15. Proc R Soc Med 1917; 10(Sect Epidemiol State Med): 44\u201360.","DOI":"10.1177\/003591571701001403"},{"issue":"2","key":"10.1016\/j.vaccine.2011.12.060_bib0035","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1017\/S0022172400017976","article-title":"Prophylactic vaccination in epidemic meningococcal meningitis","volume":"32","author":"Riding","year":"1932","journal-title":"J Hyg (Lond)"},{"issue":"6","key":"10.1016\/j.vaccine.2011.12.060_bib0040","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1172\/JCI100731","article-title":"Immunization of human subjects with specific carbohydrates of Type III and the related Type VIII pneumococcus","volume":"14","author":"Finland","year":"1935","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.vaccine.2011.12.060_bib0045","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4049\/jimmunol.29.4.285","article-title":"Cutaneous reactions and antibody response to intracutaneous injections of pneumococcus polysaccharides","volume":"29","author":"Finland","year":"1935","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2011.12.060_bib0050","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1084\/jem.52.4.573","article-title":"Cutaneous reactions in pneumonia. The development of antibodies following the intradermal injection of type-specific polysaccharide","volume":"52","author":"Francis","year":"1930","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.vaccine.2011.12.060_bib0055","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1084\/jem.80.4.299","article-title":"Preparation of the type specific polysaccharide of the type I meningococcus and a study of its effectiveness as an antigen in human beings","volume":"80","author":"Kabat","year":"1944","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.vaccine.2011.12.060_bib0060","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1084\/jem.61.6.753","article-title":"Studies on meningococcus infection: viii. The type i specific substance","volume":"61","author":"Scherp","year":"1935","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.vaccine.2011.12.060_bib0065","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/0003-9861(58)90354-0","article-title":"The effect of variation on molecular weight on the antigenicity of dextran in man","volume":"78","author":"Kabat","year":"1958","journal-title":"Arch Biochem"},{"issue":"6","key":"10.1016\/j.vaccine.2011.12.060_bib0070","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1084\/jem.129.6.1349","article-title":"Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B and group C meningococcal polysaccharides","volume":"129","author":"Gotschlich","year":"1969","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.vaccine.2011.12.060_bib0075","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.129.6.1367","article-title":"Human immunity to the meningococcus IV. Immunogenicity of group A and group C meningococcal polysaccharides","volume":"129","author":"Gotschlich","year":"1969","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.vaccine.2011.12.060_bib0080","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM197002192820803","article-title":"Prevention of meningococcal disease by group C polysaccharide vaccine","volume":"282","author":"Artenstein","year":"1970","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2011.12.060_bib0085","first-page":"197","article-title":"Control of meningococcal meningitis with meningococcal vaccines","volume":"48","author":"Artenstein","year":"1975","journal-title":"Yale J Biol Med"},{"issue":"3","key":"10.1016\/j.vaccine.2011.12.060_bib0090","first-page":"279","article-title":"Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70","volume":"45","author":"Gold","year":"1971","journal-title":"Bull World Health Org"},{"issue":"6","key":"10.1016\/j.vaccine.2011.12.060_bib0095","first-page":"645","article-title":"A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria","volume":"55","author":"Wahdan","year":"1977","journal-title":"Bull World Health Org"},{"issue":"6","key":"10.1016\/j.vaccine.2011.12.060_bib0100","first-page":"667","article-title":"A controlled field trial of a serogroup A meningococcal polysaccharide vaccine","volume":"48","author":"Wahdan","year":"1973","journal-title":"Bull World Health Org"},{"issue":"6","key":"10.1016\/j.vaccine.2011.12.060_bib0105","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.vaccine.2011.12.060_bib0110","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1172\/JCI108235","article-title":"Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants","volume":"56","author":"Gold","year":"1975","journal-title":"J Clin Invest"},{"issue":"13","key":"10.1016\/j.vaccine.2011.12.060_bib0115","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJM197709292971302","article-title":"Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age","volume":"297","author":"Peltola","year":"1977","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2011.12.060_bib0120","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1128\/IAI.66.6.2453-2459.1998","article-title":"Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine","volume":"66","author":"Maslanka","year":"1998","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2011.12.060_bib0125","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1086\/515346","article-title":"Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination","volume":"178","author":"Granoff","year":"1998","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.060_bib0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1128\/CDLI.11.1.83-88.2004","article-title":"Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A\/C polysaccharide vaccination in Saudi Arabia","volume":"11","author":"Jokhdar","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2011.12.060_bib0135","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0264-410X(99)00288-1","article-title":"4th European conference on vaccinology: societal value of vaccination. The impact of Hib conjugate vaccines in preventing invasive H. influenzae diseases in the UK","volume":"17","author":"Moxon","year":"1999","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.060_bib0140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00008480-199302000-00009","article-title":"Haemophilus influenzae type b polysaccharide-protein conjugate vaccines in children","volume":"5","author":"Eskola","year":"1993","journal-title":"Curr Opin Pediatr"},{"issue":"2","key":"10.1016\/j.vaccine.2011.12.060_bib0145","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1001\/jama.1993.03500020055031","article-title":"Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era","volume":"269","author":"Adams","year":"1993","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.060_bib0150","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/CVI.00384-09","article-title":"Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine","volume":"17","author":"Borrow","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2011.12.060_bib0155","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1128\/CVI.00420-08","article-title":"Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom","volume":"16","author":"Southern","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2011.12.060_bib0160","first-page":"R49","article-title":"Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales","volume":"7","author":"Ramsay","year":"1997","journal-title":"Commun Dis Rep CDR Rev"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2011.12.060_bib0165","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","article-title":"Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story","volume":"20","author":"Miller","year":"2001","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2011.12.060_bib0170","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1099\/0022-1317-51-9-717","article-title":"Impact of meningococcal C conjugate vaccine in the UK","volume":"51","author":"Balmer","year":"2002","journal-title":"J Med Microbiol"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2011.12.060_bib0175","doi-asserted-by":"crossref","first-page":"B20","DOI":"10.1016\/j.vaccine.2009.04.067","article-title":"Meningococcal C conjugate vaccine: the experience in England and Wales","volume":"27","author":"Campbell","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.060_bib0180","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.inf.0000195594.41449.c6","article-title":"Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands","volume":"25","author":"de Greeff","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.vaccine.2011.12.060_bib0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2807\/esm.09.07.00474-en","article-title":"Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision","volume":"9","author":"Cano","year":"2004","journal-title":"Euro Surveill"},{"issue":"3","key":"10.1016\/j.vaccine.2011.12.060_bib0190","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/INF.0b013e31819040e7","article-title":"The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada","volume":"28","author":"Bettinger","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"9431","key":"10.1016\/j.vaccine.2011.12.060_bib0195","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2011.12.060_bib0200","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.12.060_bib0205","first-page":"283","article-title":"Methods for estimating serological correlates of protection","volume":"89","author":"Siber","year":"1997","journal-title":"Dev Biol Stand"},{"issue":"5","key":"10.1016\/j.vaccine.2011.12.060_bib0210","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2011.12.060_bib0215","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1086\/314753","article-title":"Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory","volume":"179","author":"Richmond","year":"1999","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.060_bib0220","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/317646","article-title":"Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers","volume":"183","author":"Richmond","year":"2001","journal-title":"J Infect Dis"},{"issue":"9320","key":"10.1016\/j.vaccine.2011.12.060_bib0225","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","article-title":"Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination","volume":"359","author":"Maiden","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2011.12.060_bib0230","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity","volume":"197","author":"Maiden","year":"2008","journal-title":"J Infect Dis"},{"issue":"7385","key":"10.1016\/j.vaccine.2011.12.060_bib0235","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"BMJ"},{"issue":"24","key":"10.1016\/j.vaccine.2011.12.060_bib0240","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1003812","article-title":"Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans","volume":"364","author":"Sow","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2011.12.060_bib0245","doi-asserted-by":"crossref","unstructured":"Yogev R, Tan T. Meningococcal disease: The advances and challenges of meningococcal disease prevention. Hum Vaccin 2011; 7(8)epub.","DOI":"10.4161\/hv.7.8.16270"},{"issue":"5","key":"10.1016\/j.vaccine.2011.12.060_bib0250","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunologic response of man to group B meningococcal polysaccharide vaccines","volume":"126","author":"Wyle","year":"1972","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.060_bib0255","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/IAI.37.1.271-280.1982","article-title":"Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens","volume":"37","author":"Frasch","year":"1982","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2011.12.060_bib0260","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1084\/jem.144.2.319","article-title":"Protection against group B meningococcal disease. I. Comparison of group-specific and type-specific protection in the chick embryo model","volume":"144","author":"Frasch","year":"1976","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.vaccine.2011.12.060_bib0265","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1128\/IAI.47.2.527-533.1985","article-title":"Immunity and protection of mice against Neisseria meningitidis group B by vaccination, using polysaccharide complexed with outer membrane proteins: a comparison with purified B polysaccharide","volume":"47","author":"Moreno","year":"1985","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2011.12.060_bib0270","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1172\/JCI109383","article-title":"Complex of meningococcal group B polysaccharide and type 2 outer membrane protein in man","volume":"63","author":"Zollinger","year":"1979","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.vaccine.2011.12.060_bib0275","first-page":"133","article-title":"Meningococcal group B vaccine trial in Norway 1981\u20131982. Preliminary report of results available November 1982","volume":"6","author":"Froholm","year":"1983","journal-title":"NIPH Ann"},{"key":"10.1016\/j.vaccine.2011.12.060_bib0280","first-page":"129","article-title":"Polysialic acid \u2013 a glycoprotein carbohydrate involved in neural adhesion and bacterial meningitis","author":"Finne","year":"1985","journal-title":"TIBS"},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.060_bib0285","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1128\/IAI.5.1.98-102.1972","article-title":"Classification of Neisseria meningitidis Group B into distinct serotypes I. serological typing by a microbacterial method","volume":"5","author":"Frasch","year":"1972","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2011.12.060_bib0290","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4049\/jimmunol.109.4.824","article-title":"Affinity chromatography of anti-meningococcal antiserum","volume":"109","author":"Winkelhake","year":"1972","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.060_bib0295","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1084\/jem.140.1.87","article-title":"An outer membrane protein of Neisseria meningitidis group B responsible for serotype specificity","volume":"140","author":"Frasch","year":"1974","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.vaccine.2011.12.060_bib0300","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/infdis\/137.6.728","article-title":"Safety and immunogenicity of a Neisseria meningitidis Type 2 protein vaccine in animals and humans","volume":"137","author":"Zollinger","year":"1978","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2011.12.060_bib0305","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1128\/IAI.57.5.1590-1598.1989","article-title":"Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination","volume":"57","author":"Mandrell","year":"1989","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2011.12.060_bib0310","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0882-4010(87)90059-3","article-title":"Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B: 15: P1. 16 in infant rat infection model; new prospects for vaccine development","volume":"3","author":"Saukkonen","year":"1987","journal-title":"Microb Pathogen"},{"issue":"4","key":"10.1016\/j.vaccine.2011.12.060_bib0315","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0264-410X(89)90194-1","article-title":"Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay","volume":"7","author":"Saukkonen","year":"1989","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2011.12.060_bib0320","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1084\/jem.138.5.1156","article-title":"Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis","volume":"138","author":"Devoe","year":"1973","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.vaccine.2011.12.060_bib0325","first-page":"233","article-title":"Second generation meningococcal OMP-LPS vaccines","volume":"14","author":"Poolman","year":"1991","journal-title":"NIPH Ann"},{"issue":"6","key":"10.1016\/j.vaccine.2011.12.060_bib0330","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/BF00415493","article-title":"Appearance of new strains associated with group B meningococcal disease and their use for rapid vaccine development","volume":"53","author":"Frasch","year":"1987","journal-title":"Antonie van Leeuwenhoek"},{"issue":"2","key":"10.1016\/j.vaccine.2011.12.060_bib0335","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.060_bib0340","doi-asserted-by":"crossref","first-page":"16","DOI":"10.37757\/MR2007V9.N1.6","article-title":"Cuban meningococcal BC vaccine: experiences & contributions from 20 years of application","volume":"9","author":"Padron","year":"2007","journal-title":"MEDICC Review"},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.060_bib0345","doi-asserted-by":"crossref","first-page":"5","DOI":"10.37757\/MR2007V9.N1.2","article-title":"Cuba's national immunization program","volume":"9","author":"Reed","year":"2007","journal-title":"MEDICC Rev"},{"issue":"8827","key":"10.1016\/j.vaccine.2011.12.060_bib0350","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil","volume":"340","author":"de Moraes","year":"1992","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2011.12.060_bib0355","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","article-title":"Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1. 3) outer membrane protein vaccine in Iquique, Chile. Chilean national committee for meningococcal disease","volume":"13","author":"Boslego","year":"1995","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2011.12.060_bib0360","first-page":"67","article-title":"Production, characterization and control of MenB-vaccine Folkehelsa: an outer membrane vesicle vaccine against group B meningococcal disease","volume":"14","author":"Fredriksen","year":"1991","journal-title":"NIPH Ann"},{"issue":"7-8","key":"10.1016\/j.vaccine.2011.12.060_bib0365","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2011.12.060_bib0370","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1128\/CVI.00047-06","article-title":"Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine","volume":"13","author":"Feiring","year":"2006","journal-title":"Clin Vaccine Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2011.12.060_bib0375","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1128\/IAI.63.12.4642-4652.1995","article-title":"Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine","volume":"63","author":"Rosenqvist","year":"1995","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2011.12.060_bib0380","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/514232","article-title":"Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland","volume":"177","author":"Perkins","year":"1998","journal-title":"J Infect Dis"},{"issue":"7-8","key":"10.1016\/j.vaccine.2011.12.060_bib0385","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0264-410X(98)00259-X","article-title":"Human IgG subclass responses in realtion to serum bactericidal and opsonic activities after immunisation with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine","volume":"17","author":"Naess","year":"1999","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2011.12.060_bib0390","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"issue":"1200","key":"10.1016\/j.vaccine.2011.12.060_bib0395","first-page":"U1015","article-title":"The New Zealand meningococcal vaccine strategy: a tailor-made vaccine to combat a devastating epidemic","volume":"117","author":"Sexton","year":"2004","journal-title":"N Z Med J"},{"issue":"1200","key":"10.1016\/j.vaccine.2011.12.060_bib0400","first-page":"1","volume":"117","author":"Sexton","year":"2004","journal-title":"N Z Med J"},{"issue":"17-18","key":"10.1016\/j.vaccine.2011.12.060_bib0405","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2011.12.060_bib0410","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1016\/j.vaccine.2007.01.023","article-title":"Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand","volume":"25","author":"Oster","year":"2007","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2011.12.060_bib0415","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/adc.2009.180596","article-title":"Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers","volume":"96","author":"Jackson","year":"2011","journal-title":"Arch Dis Child"},{"issue":"2","key":"10.1016\/j.vaccine.2011.12.060_bib0420","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ije\/dyn228","article-title":"Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years","volume":"38","author":"Galloway","year":"2009","journal-title":"Int J Epidemiol"},{"issue":"47","key":"10.1016\/j.vaccine.2011.12.060_bib0425","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1016\/j.vaccine.2008.08.062","article-title":"MeNZB(TM) vaccine and epidemic control: when do you stop vaccinating?","volume":"26","author":"Loring","year":"2008","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2011.12.060_bib0430","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1128\/IAI.62.10.4419-4424.1994","article-title":"Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy","volume":"62","author":"Milagres","year":"1994","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2011.12.060_bib0435","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/aje\/kwm147","article-title":"A prospective study of the effectiveness of the New Zealand meningococcal B vaccine","volume":"166","author":"Kelly","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"10","key":"10.1016\/j.vaccine.2011.12.060_bib0440","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1128\/IAI.66.10.4755-4761.1998","article-title":"Specificity of bactericidal antibody response to serogroup B meningococcal strains in brazilian children after immunization with an outer membrane vaccine","volume":"66","author":"Milagres","year":"1998","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2011.12.060_bib0445","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/CVI.13.4.486-491.2006","article-title":"The VR2 epitope on the PorA P1. 7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2011.12.060_bib0450","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jmb.2005.06.061","article-title":"Crystal structure of an anti-meningococcal subtype P1. 4 porA antibody provides basis for peptide-vaccine design","volume":"351","author":"Oomen","year":"2005","journal-title":"J Mol Biol"},{"issue":"11-12","key":"10.1016\/j.vaccine.2011.12.060_bib0455","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.vaccine.2003.09.042","article-title":"Recombinant meningococcal PorA protein, expressed using a vector system with potential for human vaccination, induces a bactericidal immune response","volume":"22","author":"Humphries","year":"2004","journal-title":"Vaccine"},{"issue":"9-10","key":"10.1016\/j.vaccine.2011.12.060_bib0460","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0264-410X(02)00546-7","article-title":"Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes","volume":"21","author":"Arigita","year":"2003","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2011.12.060_bib0465","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1099\/00221287-139-8-1729","article-title":"Immunization with synthetic peptides containing epitopes of the class 1 outer-membrane protein of Neisseria meningitidis: production of bactericidal antibodies on immunization with a cyclic peptide","volume":"139","author":"Christodoulides","year":"1993","journal-title":"J Gen Microbiol"},{"issue":"8","key":"10.1016\/j.vaccine.2011.12.060_bib0470","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1128\/IAI.60.8.3156-3161.1992","article-title":"Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein","volume":"60","author":"van der Ley","year":"1992","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2011.12.060_bib0475","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1128\/IAI.72.10.5955-5962.2004","article-title":"Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design","volume":"72","author":"Urwin","year":"2004","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2011.12.060_bib0480","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0264-410X(95)98264-B","article-title":"Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine","volume":"13","author":"van der Ley","year":"1995","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2011.12.060_bib0485","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/0264-410X(96)00020-5","article-title":"Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine","volume":"14","author":"Claassen","year":"1996","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2011.12.060_bib0490","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/0264-410X(96)00001-1","article-title":"Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine","volume":"14","author":"Peeters","year":"1996","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2011.12.060_bib0495","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/S0264-410X(99)00423-5","article-title":"Immunogenicity and safety of a hexavalent meningococcal outer-membrane- vesicle vaccine in children of 2\u20133 and 7\u20138 years of age","volume":"18","author":"de Kleijn","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.12.060_bib0500","series-title":"Proceedings of the 14th International Pathogenic Neisseria Conference","article-title":"From Hexamen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine","author":"van den Dobbelsteen","year":"2004"},{"key":"10.1016\/j.vaccine.2011.12.060_bib0505","unstructured":"van den Dobbelsteen GP. NonaMen, a multivalent MenB OMV vaccine, from development to clinical trials. Vaccimonitor 18, 18. 2009."},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.060_bib0510","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1574-6976.2006.00053.x","article-title":"Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"},{"issue":"43","key":"10.1016\/j.vaccine.2011.12.060_bib0515","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1016\/j.vaccine.2010.08.048","article-title":"A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA","volume":"28","author":"Keiser","year":"2010","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2011.12.060_bib0520","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1016\/j.vaccine.2010.05.006","article-title":"Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine","volume":"28","author":"Zollinger","year":"2010","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2011.12.060_bib0525","doi-asserted-by":"crossref","first-page":"8738","DOI":"10.1074\/jbc.M808831200","article-title":"Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086","volume":"284","author":"Mascioni","year":"2008","journal-title":"J Biol Chem"},{"issue":"37","key":"10.1016\/j.vaccine.2011.12.060_bib0530","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease","volume":"28","author":"Jiang","year":"2010","journal-title":"Vaccine"},{"issue":"29","key":"10.1016\/j.vaccine.2011.12.060_bib0535","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5459","key":"10.1016\/j.vaccine.2011.12.060_bib0540","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.vaccine.2011.12.060_bib0545","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"issue":"12","key":"10.1016\/j.vaccine.2011.12.060_bib0550","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.4049\/jimmunol.176.12.7566","article-title":"Functional significance of factor H binding to Neisseria meningitidis","volume":"176","author":"Schneider","year":"2006","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.060_bib0555","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance","volume":"177","author":"Madico","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2011.12.060_bib0560","unstructured":"Richmond P, Marshall H, Sheldon E, Jiang Q, Anderson A, Jansen K, et al. Safety & immunogenicity of serogroup B Neisseria meningitidis (MnB) rLP2086 vaccine in adults and adolescent subjects: overview of 3 clinical trials. 17th International Pathogenic Neisseria Conference: Programme and Abstract Guide, 37. 2010."},{"key":"10.1016\/j.vaccine.2011.12.060_bib0565","unstructured":"Richmond P, Marshall H, Nissen MD, Lambert S, Jones T, Gruber W, et al. A randomized, observer-blinded, active control, phase 1 trial of meningococcal serogroup B rLP2086 vaccine in healthy children and adolescents aged 8 to 14 years. 16th International Pathogenic Neisseria Conference, Rotterdam, the Netherlands, 270. 2008."},{"key":"10.1016\/j.vaccine.2011.12.060_bib0570","unstructured":"Marshall H, Nissen MD, Richmond P, Lambert S., Robertson DM, Jones T, et al. A randomized, placebo-controlled, double-blind, phase 1 trial of ascending doses of meningococcal group B rLP2086 vaccine in healthy adults. 16th International Pathogenic Neisseria Conference, Rotterdam, the Netherlands, 271. 2008."},{"issue":"5","key":"10.1016\/j.vaccine.2011.12.060_bib0575","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1586\/erv.11.32","article-title":"A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease","volume":"10","author":"Su","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"10.1016\/j.vaccine.2011.12.060_bib0580","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.vaccine.2010.12.039","article-title":"A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression","volume":"29","author":"Keiser","year":"2011","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2011.12.060_bib0585","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization\u2014international meeting report Emory University, Atlanta, Georgia, United States, 16\u201317 March 2005","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.060_bib0590","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/eji.1830210103","article-title":"Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration","volume":"21","author":"Michaelsen","year":"1991","journal-title":"Eur J Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2011.12.060_bib0595","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1128\/IAI.00411-07","article-title":"Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis","volume":"75","author":"Weynants","year":"2007","journal-title":"Infect Immun"},{"issue":"45","key":"10.1016\/j.vaccine.2011.12.060_bib0600","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2011.12.060_bib0605","unstructured":"McNeil LK, Zlotnick GW, Camposano E, Logan SM, Novikova E, Zhao XJ, et al. Development of a meningococcal antigen surface expression (MEASURE) assay for the phenotypic characterization of fhbp expression by Neisseria meningitidis. 11th EMGM Meeting.Ljubljana, Slovenija, 18\u201320 May 2011."},{"issue":"2","key":"10.1016\/j.vaccine.2011.12.060_bib0610","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.vaccine.2011.11.050","article-title":"Capsule null locus meningococci: Typing of antigens used in an investigational multicomponent meningococcus serogroup B vaccine","volume":"30","author":"Claus","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2011.12.060_bib0615","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1128\/JB.01308-09","article-title":"Expression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNR-regulated promoter","volume":"192","author":"Oriente","year":"2010","journal-title":"J Bacteriol"},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.060_bib0620","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/MMBR.68.1.154-171.2004","article-title":"Iron transport systems in Neisseria meningitidis","volume":"68","author":"Perkins-Balding","year":"2004","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.vaccine.2011.12.060_bib0625","doi-asserted-by":"crossref","unstructured":"Metruccio MME, Pigozzi E, Roncarati D, Berlanda Scorza F, Norais N, Hill SA, et al. A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements. PLoS Pathog. 2009;5(12): e1000710.","DOI":"10.1371\/journal.ppat.1000710"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11019955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11019955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T20:00:33Z","timestamp":1687464033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11019955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":125,"alternative-id":["S0264410X11019955"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.12.060","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}